TNX 1700
Alternative Names: mTNX-1700; Recombinant Trefoil Family Factor 2; rTFF2; TNX-1700; Trefoil Family Factor 2 - Tonix PharmaceuticalsLatest Information Update: 28 Nov 2025
At a glance
- Originator Columbia University
- Developer Columbia University; Tonix Pharmaceuticals Holding Corp
- Class Anti-inflammatories; Antineoplastics; Biological factors; Recombinant fusion proteins
- Mechanism of Action Trefoil factor-2 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Gastric cancer; Pancreatic cancer
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 28 Nov 2025 No recent reports of development identified for preclinical development in Gastric-cancer in USA
- 02 Jul 2025 Pharmacodynamics data from a preclinical trial in Gastric cancer released by Tonix Pharmaceuticals